Rilpivirine + darunavir/cobicistat — Competitive Intelligence Brief

Rilpivirine + darunavir/cobicistat (Rilpivirine + darunavir/cobicistat) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiretroviral combination (NNRTI + protease inhibitor + pharmacokinetic booster). Area: Infectious Disease (HIV/AIDS).

marketed Antiretroviral combination (NNRTI + protease inhibitor + pharmacokinetic booster) HIV reverse transcriptase, HIV protease Infectious Disease (HIV/AIDS) Small molecule

Target snapshot

Rilpivirine + darunavir/cobicistat (Rilpivirine + darunavir/cobicistat) — A.O. Ospedale Papa Giovanni XXIII. This combination inhibits HIV reverse transcriptase and protease to block viral replication, with cobicistat enhancing darunavir levels.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Rilpivirine + darunavir/cobicistat TARGET	Rilpivirine + darunavir/cobicistat	A.O. Ospedale Papa Giovanni XXIII	marketed	Antiretroviral combination (NNRTI + protease inhibitor + pharmacokinetic booster)	HIV reverse transcriptase, HIV protease
All licensed antiretroviral medications	All licensed antiretroviral medications	University of Minnesota	marketed	Antiretroviral agents (multiple classes: NRTIs, NNRTIs, PIs, INSTIs, entry inhibitors)	Multiple (HIV reverse transcriptase, HIV protease, HIV integrase, CCR5, CXCR4, gp120/gp41)
Symtuza® (TAF/FTC/DRV/c)	Symtuza® (TAF/FTC/DRV/c)	Fundacion SEIMC-GESIDA	marketed	Antiretroviral combination (NRTI/INSTI class with protease inhibitor)	HIV reverse transcriptase, HIV protease, CYP3A4
tenofovir + emtricitabine + atazanavir-ritonavir	tenofovir + emtricitabine + atazanavir-ritonavir	Juan A. Arnaiz	marketed	Antiretroviral combination (NRTI + PI/r)	HIV reverse transcriptase, HIV protease
First-line Antiretroviral Therapy	First-line Antiretroviral Therapy	UPECLIN HC FM Botucatu Unesp	marketed	Antiretroviral combination therapy (NRTI/NNRTI/PI/INSTI)	HIV reverse transcriptase, HIV protease, HIV integrase (depending on regimen components)
Standard Triple	Standard Triple	University of Alberta	marketed	Antiretroviral combination therapy	HIV reverse transcriptase, HIV protease (depending on formulation)
Different HAART regimens	Different HAART regimens	Danish HIV Research Group	marketed	Antiretroviral combination therapy	HIV reverse transcriptase, HIV protease, HIV integrase (depending on regimen composition)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiretroviral combination (NNRTI + protease inhibitor + pharmacokinetic booster) class)

1. A.O. Ospedale Papa Giovanni XXIII · 1 drug in this class